GlassScriptPrepare for your visit
Juna Engutan
Primary Care · Ewing, NJ · NPI 1902573389
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$236.63
in general payments reported to CMS, 2019-2025 · $73.18 in 2025
The $73.18 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Who reported paying
General payments only, top 4 by amount.
- Acadia Pharmaceuticals INC $94.97
- Lilly USA, LLC $68.48
- Otsuka America Pharmaceutical, INC. $36.71
- Exact Sciences Corporation $36.47
Drugs and devices associated with these payments
Nuplazid Amyvid Rexulti Cologuard Collection Kit Mounjaro Zepbound
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Juna Engutan listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/11200560/juna-engutan